

Zydus teams up with Medicure to introduce cholesterol drug in US

08 March 2018 | News

The launch of ZYPITAMAG, which is used to manage cholesterol levels, marks the first branded product launch for Zydus in the US



Zydus Cadila has entered into a definitive agreement with US-based Medicure International Inc. to commercialise its new drug application (NDA) product pitavastatin magnesium in the US.

The launch of ZYPITAMAG, which is used to manage cholesterol levels, marks the first branded product launch for Zydus in the US

As part of this agreement, Zydus will hold the NDA and Medicure will be responsible for the sales and marketing of ZYPITAMAG.

ZYPITAMAG has been approved in strengths of 1 mg, 2 mg and 4 mg.